Pseudo-mannosylated DC-SIGN Ligands as potential adjuvants for HIV vaccines

Viruses

Volumn 6, Issue 2, 2014, Pages 391-403

  Berzi, Angela ^a   Varga, Norbert ^b   Sattin, Sara ^b   Antonazzo, Patrizio ^a   Biasin, Mara ^a   Cetin, Irene ^a   Trabattoni, Daria ^a   Bernardi, Anna ^b   Clerici, Mario ^b,c  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Adjuvant; DC SIGN; Glycomimetic compounds; HIV 1; Innate immunity; Vaccine

Indexed keywords

ADJUVANT; B7 ANTIGEN; BETA INTERFERON; CD86 ANTIGEN; DC SIGN LIGAND POLYMAN 19; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; POLYINOSINIC POLYCYTIDYLIC ACID; RANTES; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOMODULATION; INNATE IMMUNITY; MTT ASSAY; NORMAL HUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; CELL ADHESION MOLECULES; CYTOKINES; HUMANS; LECTINS, C-TYPE; LIGANDS; MANNANS; RECEPTORS, CELL SURFACE;

EID: 84893333504     PISSN: 19994915     EISSN: None     Source Type: Journal    
DOI: 10.3390/v6020391     Document Type: Article

References (28)

1. Girard, M.P.; Osmanov, S.; Assossou, O.M.; Kieny, M.P. Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: A review. Vaccine 2011, 29, 6191-6218.
2. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209-2220.
3. Hammer, S.M.; Sobieszczyk, M.E.; Janes, H.; Karuna, S.T.; Mulligan, M.J.; Grove, D.; Koblin, B.A.; Buchbinder, S.P.; Keefer, M.C.; Tomaras, G.D.; et al. Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine. N. Engl. J. Med. 2013, 369, 2083-2092.
4. MacLeod, M.K.; McKee, A.S.; David, A.; Wang, J.; Mason, R.; Kappler, J.W.; Marrack, P. Vaccine adjuvants aluminum and monophosphoryl lipid A provide distinct signals to generate protective cytotoxic memory CD8 T cells. Proc. Natl. Acad. Sci. USA 2011, 108, 7914-7919.
5. De Gregorio, E.; Caproni, E.; Ulmer, J.B. Vaccine adjuvants: Mode of action. Front. Immunol. 2013, 4, 1-5.
6. Coffman, R.L.; Sher, A.; Seder, R.A. Vaccine adjuvants: Putting innate immunity to work. Immunity 2010, 33, 492-503.
7. Casella, C.R.; Mitchell, T.C. Putting endotoxin to work for us: Monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 2008, 65, 3231-3240.
8. Akira, S. Innate immunity and adjuvants. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2011, 366, 2748-2755.
9. Lang, R.; Schoenen, H.; Desel, C. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: Findings, implications and open questions. Immunobiology 2011, 216, 1184-1191.
10. Van Kooyk, Y.; Unger, W.W.; Fehres, C.M.; Kalay, H., García-Vallejo, J.J. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol. Immunol. 2013, 55,143-145.
11. Van Kooyk, Y.; Geijtenbeek, T.B. DC-SIGN: Escape mechanism for pathogens. Nat. Rev. Immunol. 2003, 3, 697-709.
12. Svajger, U.; Anderluh, M.; Jeras, M.; Obermajer, N. C-type lectin DC-SIGN: An adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity. Cell. Signal. 2010, 22, 1397-1405.
13. Sattin, S.; Daghetti, A.; Thépaut, M.; Berzi, A.; Sánchez-Navarro, M.; Tabarani, G.; Rojo, J.; Fieschi, F.; Clerici, M.; Bernardi, A. Inhibition of DC-SIGN-mediated HIV infection by a linear trimannoside mimic in a tetravalent presentation. ACS Chem. Biol. 2010, 5, 301-312.
14. Berzi, A.; Reina, J.J.; Ottria, R.; Sutkeviciute, I.; Antonazzo, P.; Sanchez-Navarro, M.; Chabrol, E.; Biasin, M.; Trabattoni, D.; Cetin, I.; et al. A glycomimetic compound inhibits DC-SIGN-mediated HIV infection in cellular and cervical explant models. AIDS 2012, 26, 127-137.
15. Varga, N.; Sutkeviciute, I.; Guzzi, C.; McGeagh, J.; Petit-Haertlein, I.; Gugliotta, S.; Weiser, J.; Angulo, J.; Fieschi, F.; Bernardi, A. Selective targeting of DC-SIGN with mannose-based glycomimetics. Synthesis and interaction studies of bis-benzylamide derivatives of a pseudo-mannobioside. Chemistry 2013, 19, 4786-4797
16. Varga, N.; Sutkeviciute, I.; Ribeiro-Viana, R.; Berzi, A.; Ramdasi, R.; Daghetti, A.; Vettoretti, G.; Amara, A.; Clerici, M.; Rojo, J.; et al. Identification of a promising multivalent inhibitor of the DC-SIGN dependent uptake of HIV-1 and Dengue virus. Biomaterials 2014, in press.
17. Cocchi, F.; DeVico, A.L.; Garzino-Demo, A.; Arya, S.K.; Gallo, R.C.; Lusso, P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270, 1811-1815.
18. Lietz, R.; Bayer, W.; Ontikatze, T.; Johrden, L.; Tenbusch, M.; Storcksdieck Genannt Bonsmann, M.; Uberla, K.; Dittmer, U.; Wildner, O. Codelivery of the chemokine CCL3 by an adenovirus-based vaccine improves protection from retrovirus infection. J. Virol. 2012, 86, 1706-1716.
19. Schroder, K.; Hertzog, P.J.; Ravasi, T.; Hume, D.A. Interferon-gamma: An overview of signals, mechanisms and functions. J. Leukoc. Biol. 2004, 75, 63-89.
20. Maue, A.C.; Eaton, S.M.; Lanthier, P.A.; Sweet, K.B.; Blumerman, S.L.; Haynes, L. Proinflammatory adjuvants enhance the cognate helper activity of aged CD4 T cells. J. Immunol. 2009, 182, 6129-6135.
21. Ben-Sasson, S.Z.; Hu-Li, J.; Quiel, J.; Cauchetaux, S.; Ratner, M.; Shapira, I.; Dinarello, C.A.; Paul, W.E. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc. Natl. Acad. Sci. USA 2009, 106, 17119-17124.
22. Ahlers, J.D.; Dunlop, N.; Alling, D.W.; Nara, P.L.; Berzofsky, J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: Granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes. J. Immunol. 1997, 158, 3947-3958.
23. Su, B.; Wang, J.; Wang, X.; Jin, H.; Zhao, G.; Ding, Z.; Kang, Y.; Wang, B. The effects of IL-6 and TNF-alpha as molecular adjuvants on immune responses to FMDV and maturation of dendritic cells by DNA vaccination. Vaccine 2008, 26, 5111-5122.
24. Devito, C.; Broliden, K.; Kaul, R.; Svensson, L.; Johansen, K.; Kiama, P.; Kimani, J.; Lopalco, L.; Piconi, S.; Bwayo, J.J.; et al. Mucosal and plasma IgA from HIV-1-exposed uninfected individuals inhibit HIV-1 transcytosis across human epithelial cells. J. Immunol. 2000, 165, 5170-5176.
25. Miyazawa, M.; Lopalco, L.; Mazzotta, F.; Lo Caputo, S.; Veas, F.; Clerici, M. The "immunologic advantage" of HIV-exposed seronegative individuals. AIDS 2009, 23, 161-175.
26. Brooks, D.G.; Lee, A.M.; Elsaesser, H.; McGavern, D.B.; Oldstone, M.B. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J. Exp. Med. 2008, 205, 533-541.
27. Landay, A.L.; Clerici, M.; Hashemi, F.; Kessler, H.; Berzofsky, J.A.; Shearer, G.M. In vitro restoration of T cell immune function in human immunodeficiency virus-positive persons: Effects of interleukin (IL)-12 and anti-IL-10. J. Infect. Dis. 1996, 173, 1085-1091.
28. Boasso, A.; Shearer, G.M.; Clerici, M. The hunt for an HIV vaccine: Time to rethink recent failures. Lancet 2008, 371, 1897-1898.